166 related articles for article (PubMed ID: 37182432)
1. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N
Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
[TBL] [Abstract][Full Text] [Related]
3. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
[TBL] [Abstract][Full Text] [Related]
6. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
8. Germline Testing and Somatic Tumor Testing for
Kwon JS; Tinker AV; Santos J; Compton K; Sun S; Schrader KA; Karsan A
JCO Precis Oncol; 2022 Oct; 6():e2200033. PubMed ID: 36265114
[TBL] [Abstract][Full Text] [Related]
9.
Lanjouw L; Mourits MJE; Bart J; Ter Elst A; Berger LPV; van der Hout AH; Alam N; de Bock GH
Int J Gynecol Cancer; 2023 Aug; 33(8):1260-1269. PubMed ID: 37137525
[TBL] [Abstract][Full Text] [Related]
10. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
[TBL] [Abstract][Full Text] [Related]
11. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
[TBL] [Abstract][Full Text] [Related]
13.
Harriman JW; Espinel WF; Vagher J; Gammon A
JCO Precis Oncol; 2022 Oct; 6():e2100375. PubMed ID: 36201716
[TBL] [Abstract][Full Text] [Related]
14. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
15.
Talwar V; Rauthan A
Indian J Cancer; 2022 Mar; 59(Supplement):S56-S67. PubMed ID: 35343191
[TBL] [Abstract][Full Text] [Related]
16. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.
Sekine M; Enomoto T; Arai M; Yokoyama S; Nomura H; Nishino K; Ikeuchi T; Kuriyama Y; Nakamura S;
J Hum Genet; 2022 May; 67(5):267-272. PubMed ID: 34983974
[TBL] [Abstract][Full Text] [Related]
18. Predicting the likelihood of a
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
[TBL] [Abstract][Full Text] [Related]
19. Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
Vos JR; Fakkert IE; de Hullu JA; van Altena AM; Sie AS; Ouchene H; Willems RW; Nagtegaal ID; Jongmans MCJ; Mensenkamp AR; Woldringh GH; Bulten J; Leter EM; Kets CM; Simons M; Ligtenberg MJL; Hoogerbrugge N;
J Natl Cancer Inst; 2020 Feb; 112(2):161-169. PubMed ID: 31076742
[TBL] [Abstract][Full Text] [Related]
20. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
